![]() |
市場調查報告書
商品編碼
1351017
2023-2030年全球微生物發酵技術市場Global Microbial Fermentation Technology Market 2023-2030 |
預計在預測期(2023-2030年),全球微生物發酵技術市場將以5.9%的年複合成長率成長。推動全球微生物發酵技術市場成長的主要因素包括工業發酵的興起,工業發酵用於生產化學品、材料、生物燃料、膳食和藥品。採用發酵技術的主要目的是使用基於培養或分子的方法來改變代謝途徑。發酵是製藥公司生產重組產品(例如重組蛋白、疫苗和荷爾蒙)的常用方法。例如,2023 年 5 月,Ardra Inc. 生產天然食品成分,如植物性肉類替代品、健康和營養添加劑以及天然防腐劑。 Ardra 透過精密發酵技術,以更永續、更實惠的方式生產天然成分,並提供可靠的供應。
全球微生物發酵技術市場按技術、應用和最終用戶細分。根據技術,市場細分為分批補料發酵、固態發酵和連續攪拌槽反應器。根據應用,市場細分為抗生素、疫苗、溶劑和中間化合物。此外,根據最終用戶,市場細分為生物製藥行業、食品和飼料行業、CRO和CMO以及學術研究機構。在最終用戶中,由於超音波、歐姆加熱、MEF、PEF和冷等離子體等新興創新技術的發展不斷成長,預計生物製藥行業細分市場將佔據相當大的市場佔有率。這些極大地改善了發酵技術的市場。
其中,抗生素細分領域預計將在全球微生物發酵技術市場中佔據相當大的佔有率。該細分市場的成長歸因於全球健康問題、製藥業投資、新菌株的發現、生物技術的進步以及對抗生素日益成長的需求的影響力不斷增強。為了提高產能,新設施和改進的流程為公司帶來了重要的永續性改善。例如,2023年2月,贏創工業股份公司的動物營養公司產品線更加關注抗菌生長促進劑,致力於提供確保動物健康和性能、保護人類健康並滿足日益成長的高需求的解決方案。全球優質動物性蛋白質。
全球微生物發酵技術市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲。其中,北美預計將在全球市場中佔據顯著佔有率。不斷變化的格局生物製品生產的成長是該地區市場的主要促進因素。該地區的主要市場參與者包括Ferment.Co、Perfect Day、Geltor, Inc.、The EVERY Co. 等。
在所有地區中,亞太地區預計在預測期內將以相當大的年複合成長率成長。公司擴大參與生物製劑研究和產品開發,以及該地區存在大量合約開發組織,都是促進區域成長的因素。由於影響生物製藥外包的因素的融合,該地區對微生物發酵技術的需求將會增加。為了滿足國內需求,中國將興建一批生物加工廠。
強而有力的監管架構是塑造亞太市場的另一個關鍵因素。印度、中國、日本繼續努力改進有關生物製藥產品的推廣、開發、批准和法律實踐的指導方針。中國是亞太地區的主要收入貢獻者。影響中國產業的關鍵因素之一是生物製劑製造方式的改變。由於生物製藥研發支出不斷增加以及 GMP 製造採用令人難以置信的創新技術,該市場不斷成長。
Title: Global Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Technology (Fed-Batch Fermentation, Solid-State Fermentation, and Continuous Stirred-Tank Reactor), by Application (Antibiotics, Vaccines, Solvents, and Intermediary compounds), and by End-Users (Bio-Pharmaceutical Industries, Food and Feed Industries, CROs and CMOs, and Academic Research Institutes),Forecast Period (2023-2030).
The global microbial fermentation technology market is anticipated to grow at a CAGR of 5.9% during the forecast period (2023-2030). The major factor driving the global microbial fermentation technology market growth includes the rising industrial fermentation, which is used to generate chemicals, materials, biofuels, meals, and medicines. The main purpose in adoption of fermentation technology is to alter the metabolic pathways using cultivation-based or molecular approaches. Fermentation is a common method used by pharmaceutical companies to manufacture recombinant goods such as recombinant proteins, vaccines, and hormones. For instance, in May 2023, Ardra Inc. produces natural food ingredients such as plant-based meat substitutes, health and nutritional additives, and natural preservatives. Ardra produces natural ingredients more sustainably, more affordably, and with reliable supply via precision fermentation technology.
The global microbial fermentation technology market is segmented by technology, application, and end-users. Based on the technology, the market is sub-segmented into fed-batch fermentation, solid-state fermentation, and continuous stirred-tank reactors. Based on the application, the market is sub-segmented into antibiotics, vaccines, solvents, and intermediary compounds. Further, on the basis of end-users, the market is sub-segmented into bio-pharmaceutical industries, food and feed industries, CROs and CMOs, and academic research institutes. Among the end-users, the bio-pharmaceutical industries sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of emerging innovative technologies such as ultrasound, ohmic heating, MEF, PEF, and cold plasma, these have significantly improved the market for fermentation technologies.
Among the application, the antibiotic sub-segment is expected to hold a considerable share of the global microbial fermentation technology market. The segmental growth is attributed to the growing influence of global health concerns, pharmaceutical industry investment, the discovery of new strains, advancements in biotechnology, and the increasing need for antibiotics. To boost production capacity, the new facilities and improved processes bring important sustainability improvements for the company. For instance, in February 2023, Evonik Industries AG's Animal Nutrition Company Line, with a larger focus on antimicrobial growth promoters, strives to offer solutions that assure the health and performance of the animal, protect human health, and meet the growing demand for high-quality animal protein globally.
The global microbial fermentation technology market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe. The evolving landscape of the manufacturing of biologics is a major driving factor for the market in the region. The key market players in the region include Ferment.Co, Perfect Day, Geltor, Inc., The EVERY Co. and others.
Among all regions, the Asia-Pacific regions is anticipated to grow at a considerable CAGR over the forecast period. Growing company involvement in biologics research and product development, together with the presence of a sizable number of contract development organizations in the area, are both factors contributing to regional growth. The region's need for microbial fermentation technology would rise as a result of the convergence of the factors affecting biopharmaceutical outsourcing. To address domestic demand, a number of bioprocessing plants are going to be built in China.
The strong regulatory framework is another key factor in shaping the Asia-Pacific market. India, China, Japan continues to make attempts to improve guidelines regarding the promotion, development, approval, and legal practice surrounding biopharmaceutical products. China is the key revenue contributor in the Asia-Pacific region. One of the key factors influencing the Chinese industry is the way biologics manufacturing is changing. The market has grown as a result of growing spending for biopharmaceutical research and development as well as the adoption of incredibly innovative technology for GMP manufacturing.
The major companies serving the global microbial fermentation technology market includes Abolis Biotechnologies, BioVectra Inc., Microbial Discovery Group, Novozymes A/S, TerraVia Holdings, Inc., and others. The market players are considerably contributing to market growth through the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, Novus International Inc., a multinational animal feed and health firm, acquired Agrivida Inc. As a result of the acquisition, Novus has control of the patented INTERIUS technology that Agrivida created to embed feed ingredients inside grain.